EPHA2 and colorectal carcinoma: EPHA2 has recently been identified as a clinically relevant biomarker in CRC patients as a poor prognostic marker in UICC stage II/III CRC patients owing to its ability to promote migration and invasion (Dunne et al. 2016; Robertis et al. 2017; Cioce and Fazio 2021, Figure 1).